异动解读 | 巨子生物股价盘中大涨6.86% 主力产品获优先审批 增强长期发展信心

异动解读
06 Dec 2024

生物科技公司巨子生物(02367)今日盘中大涨6.86%,引起市场广泛关注。

利好消息是,巨子生物旗下主力产品"注射用重组胶原蛋白填充剂"获得国家药监局批准优先审评。该产品属于国家重点研发计划范畴,有望加快上市进程。

作为巨子生物重要收入来源,这款产品的利好消息无疑增强了市场对公司长期发展前景的信心。投资者预期公司未来将从产品上市销售中获益,推升股价大涨。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10